Heart Disease and Amarin

Selected Headlines

Date Headline (link) Source Relevant Snippet
3/30/2021 Amarin's heart drug Vazkepa gets European Commission approval Amarin‚Aos heart drug Vazkepa gets European Commission approval 33 AM(Reuters) - The European Commission has granted Amarin Corporation Plc's fish-oil derived heart drug Vazkepa marketing authorization in the European Union, the drugmaker said ... type of blood fat that can increase the risk of heart disease. In December 2019, U.S. health regulators approved expanding the drug's label to include its heart benefit claims.(Reporting by Vishwadha Chander in Bengaluru ...
3/30/2021 European Commission clears Amarin's fish-oil derived heart drug Vazkepa MSN Reuters) - The European Commission has granted Amarin Corporation Plc's fish-oil derived heart drug Vazkepa marketing authorization in the European Union, the drugmaker said on Tuesday.The authorization allows Amarin to market Vazkepa - sold in ... type of blood fat that can increase the risk of heart disease. In December 2019, U.S. health regulators approved expanding the drug's label to include its heart benefit claims.(Reporting by Vishwadha Chander in Bengaluru ...
3/30/2021 Amarin's heart drug Vazkepa gets European Commission approval Cardiovascular Events , European Commission , Fish Oil , Heart Attacks , Marketing Authorization Application (MAA) , Strokes , Therapeutics , TriglyceridesAmarin‚Aos heart drug Vazkepa gets European Commission approval (Reuters) ‚Ai The European Commission has granted Amarin Corporation Plc‚Aos ... type of blood fat that can increase the risk of heart disease. In December 2019, U.S. health regulators approved expanding the drug‚Aos label to include its heart benefit claims.Reporting by Vishwadha Chander in ...
9/8/2020 Vascepa Generics; Apple Watch Captures STEMI; COVID-19 Hit 1 in 3 Cath Labs' Staff Recent developments of interest in cardiovascular medicine by Crystal Phend , Senior Editor, MedPage Today Generics for icosapent ethyl (Vascepa) came a step closer, with an appeals court affirming Amarin's patents are invalid. ( Endpoints News ) But Amarin announced a pragmatic trial of the fish-oil derived drug for prevention of COVID-19 and other respiratory infection complications in older adults with heart disease. (Yahoo! News) Putting the Apple Watch Series 4 ...
9/4/2020 Appeals Court Deals Blow to Patent Protections for Amarin’s Vascepa | BioSpace BioSpace Appeals Court Deals Blow to Patent Protections for Amarin’s Vascepa Published: Sep 04, 2020 By Alex Keown Shares of Amarin Corporation are down more than 3% in premarket trading after the company reported Thursday that a panel of three judges from the U.S. Court of Appeals upheld a lower court’s ruling that paved the way for generic competition for the company’s heart disease drug, Vascepa. Amarin reported the court upheld ...
9/4/2020 Appeals Court Deals Blow to Patent Protections for Amarin’s Vascepa Appeals Court Deals Blow to Patent Protections for Amarin’s Vascepa Published: Sep 04, 2020 BioSpace Shares of Amarin Corporation are down more than 3% in premarket trading after the company reported Thursday that a panel of three judges from the U.S. Court of Appeals upheld a lower court’s ruling that paved the way for generic competition for the company’s heart disease drug, Vascepa. Amarin reported the court upheld a March ...
9/3/2020 Amarin Defeated Appeal Reigns Over Vascepa Heart Drug (1) – Bloomberg Law ... Amarin Defeated Appeal Reigns Over Vascepa Heart Drug (1) – Bloomberg Law Amarin Defeated Appeal Reigns Over Vascepa Heart Drug (1) – Bloomberg Law Amarin Defeated in Vascepa Heart Drug Appeal Court (1) Bloomberg Law Why Amarin Stock Is Slammed Now The Motley Fool Why Amarin Shares Shares Wednesday Benzinga Amarin Plummets After Patent Appeal Demonstrates Major Bloomberg Risk Drug Sales Amarin loses appeal of patent for heart disease, allowing commercial STAT ...
8/9/2020 Amarin’s Vascepa To Take Part In Covid-19 Study In Adults With Heart Disease Bitcoin Ethereum News Amarin announced on Friday that Kaiser Permanente Northern California (KPNC) is initiating a trial to study the potential of its lead product Vascepa to be used as a treatment to prevent or reduce the risk of complications from viral respiratory illnesses such as COVID-19 in older adults with heart disease. Biotech Amarin ( AMRN ) said that that the MITIGATE COVID-19 study, will test the effects of ...
8/9/2020 Amarin’s Vascepa To Take Part In Covid-19 Study In Adults With Heart Disease Amarin announced on Friday that Kaiser Permanente Northern California (KPNC) is initiating a trial to study the potential of its lead product Vascepa to be used as a treatment to prevent or reduce the risk of complications from viral respiratory illnesses such as COVID-19 in older adults with heart disease. Biotech Amarin ( AMRN ) said that that the MITIGATE COVID-19 study, will test the effects of Vascepa on viral ...
3/31/2020 Amarin's Vascepa Loses Patent Protection in Court Battle, Shares Plunge | BioSpace BioSpace Amarin's Vascepa Loses Patent Protection in Court Battle, Shares Plunge Published: Mar 31, 2020 By Alex Keown Shares of Amarin Corporation are down more than 70% in premarket trading after a judge ruled that generic companies can go ahead and seek approval of generic versions of the company’s heart disease drug, Vascepa. On Monday, a judge from the U.S. District Court for the District of Nevada ruled against patents blocking ...
1/15/2020 Dr. Deepak L. Bhatt discusses New FDA Approved Medication to Reduce Cardiovascular Health Risks PRWeb ... discuss this medication. A video accompanying this announcement is available at: https://youtu.be/wzlFv28Ystg The medication, VASCEPA® (icosapent ethyl) from Amarin, is the first-and-only FDA-approved therapy for reducing CVD risk for indicated ... Association listed this approval as one of the 2019 Top Heart Disease and Stroke Research Advances, placing it among studies the selection committee called “momentous for our patients.” Additionally, independent third-party analyses have found ...
1/3/2020 Amarin Risks Getting Exposed as a Paper Tiger Yahoo News ... investment sectors that at least have a semblance of predictability, the pharmaceutical industry is notoriously volatile. Case in point is Amarin (NASDAQ: AMRN ). Specializing in an omega-3-based treatment called Vascepa, the drug is ... of the underlying lucrative market — about 630,000 Americans die from heart disease annually — it attracts several competitors . Oppenheimer analysts reported that off-label use of Vascepa is already at sky-high levels. That’s unlikely to ...
12/24/2019 How the New FDA-Approved Fish Oil Drug Can Help Your Heart ... cardiovascular events like heart attacks, strokes, and death in at-risk patients. Vascepa, which is produced by the drug manufacturer Amarin Pharma Inc., is the first drug of its kind to help cut cardiovascular risk ... Vascepa significantly lowered people’s cardiovascular risk and triglyceride levels. As heart disease is the leading cause of death Trusted Source in the United States, health experts are optimistic about the treatment option, which could benefit ...
12/21/2019 Amarin’s fish-oil pill is now available to millions more patients, but it’s still no Lipitor - MarketWatch MarketWatch A long-awaited label expansion for Amarin Corp.’s prescription fish-oil medication puts Vascepa on track for millions of dollars in new revenue. But the new indication also comes with a much more limited ... taking statins, which are considered the standard of care in heart disease. High levels of triglycerides are linked to heart problems. In addition, patients must have been diagnosed with heart disease or diabetes, plus have ...
12/21/2019 Amarin’s fish-oil pill is now available to millions more patients, but it’s still no Lipitor – Trade For Profit Share A long-awaited label expansion for Amarin Corp.’s prescription fish-oil medication puts Vascepa on track for millions of dollars in new revenue. But the new indication also comes with a much more ... taking statins, which are considered the standard of care in heart disease. High levels of triglycerides are linked to heart problems. In addition, patients must have been diagnosed with heart disease or diabetes, plus have ...
12/19/2019 Why Longer-Term Investors Should Buy Amarin Stock on Weakness ... reserved. 9201 Corporate Blvd, Rockville, MD 20850. Breaking news Home / Stock Picks / Hot Stocks / Why Longer-Term Investors Should Buy Amarin Stock on Weakness Why Longer-Term Investors Should Buy Amarin Stock on Weakness Some ... levels who are taking statins (cholesterol-lowering drugs) and have heart disease. The drugs watchdog also approved the treatement for patients who have diabetes and two other risk factors for heart disease. Previously, the agency ...
12/18/2019 FDA approves omega-3 fatty acid to reduce cardiovascular risk ... 18 DEC 2019 The US Food and Drug Administration (FDA) has approved the omega-3 fatty acid icosapent ethyl (Vascepa; Amarin Pharma) as an adjunctive therapy to reduce the risk of cardiovascular events in adults ... patients with elevated triglycerides and other important risk factors, including heart disease, stroke and diabetes, an adjunctive treatment option that can help decrease their risk of cardiovascular events,” he added. Vascepa, which is taken orally ...
12/17/2019 U.S. approves fish oil-based drug for cutting heart risks Philly Tribune ... heart disease and diabetes. In patient testing, it reduced risks of potentially deadly complications including heart attacks and strokes about 25%. Amarin, the drug’s maker, set a list price of $303.65 per month. What patients pay will vary by insurance, and Amarin said it will offer financial help. The Irish drugmaker estimates the new approval makes Vascepa, which is pronounced vas-EE’-puh and also is called icosapent ethyl, appropriate ...
12/17/2019 It’s All About the Marketing for Amarin It’s All About the Marketing for Amarin Posted on Tuesday, December 17th, 2019 by Chris Markoch Share by Email Amarin (NASDAQ: AMRN ) stock is rising on news that their only product, Vascepa, was approved to ... already be taking statins (considered the standard of care in heart disease). Second patients must have a diagnosis of heart disease or diabetes. Finally, they must have at least two other risk factors for cardiovascular ...
12/16/2019 FDA Approves Expanded Use Of Fish-Oil Based Drug For Patients With Multiple Risk Factors | Kaiser Health News Kaiser Health News ... decades of mixed results for fish-oil-based drugs and could result in Vascepa being prescribed to millions of patients. Amarin, the drug's maker, set a list price of $303.65 per month. The Associated Press ... extreme, triglyceride levels who have multiple risk factors such as heart disease and diabetes. (Johnson, 12/13) The Wall Street Journal: FDA Approves Fish-Oil-Derived Drug For Use Preventing Heart Attacks, Strokes The drug, Vascepa ...
12/16/2019 Amarin’s fish-oil pill now available to millions more patients. But it’s still no Lipitor - MarketWatch MarketWatch A long-awaited label expansion for Amarin Corp.’s prescription fish-oil medication puts Vascepa on track for millions of dollars in new revenue. But the new indication also comes with a much more limited ... taking statins, which are considered the standard of care in heart disease. High levels of triglycerides are linked to heart problems. In addition, patients must have been diagnosed with heart disease or diabetes, plus have ...
12/16/2019 FDA broadens approval for fish-oil derived heart disease drug ... heart disease, or reduced all-cause mortality. Vascepa was initially approved by the FDA in 2012 to treat patients with severe triglyceride levels. The drug essentially takes one particular fatty acid found in fish oil, called eicosapentaenoic acid (EPA), and delivers it in a purified concentrated form. The highly limited nature of Vascepa’s approval resulted in several years of conflict between the FDA and the drug’s developer Amarin. Amarin unsurprisingly ...
12/16/2019 FDA approves fish oil-based drug for cutting heart risks ... drug for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills. This file photo provided by Amarin in November 2018 shows a capsule of the purified, prescription fish oil Vascepa. On ... extreme, triglyceride levels who have multiple risk factors such as heart disease and diabetes. In patient testing, it reduced risks of potentially deadly complications, including heart attacks and strokes, by about 25%. Amarin, the drug’s ...
12/16/2019 US approves fish oil-based drug for cutting heart risks | Health | phillytrib.com Philly Tribune US approves fish oil-based drug for cutting heart risks LINDA A. JOHNSON SMS This undated photo provided by Amarin in November 2018 shows a capsule of the purified, prescription fish oil Vascepa. On Friday ... extreme, triglyceride levels who have multiple risk factors such as heart disease and diabetes. In patient testing, it reduced risks of potentially deadly complications including heart attacks and strokes about 25%. Amarin, the drug's maker ...
12/16/2019 Amarin Calls Pop After Big FDA Ruling Amarin Calls Pop After Big FDA Ruling The FDA approved AMRN's Vascepa for broader use by Patrick Martin Published on Dec 16, 2019 at 10:12 AM Updated on Dec 16, 2019 at 10:12 AM AMRN ... FDA) approved Vascepa -- the drugmaker's fish-oil derived treatment for heart disease -- for broader use. In response, Oppenheimer upped its price target to $8 from $7, while Citigroup said it expects the label expansion to ...